Bliss GVS Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Bliss GVS Pharma Ltd. on BSE

Load latest

Bliss GVS Pharma Ltd.

12 Jul 2024

152.19

-0.84%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, …

BSE India

Please find enclosed herewith a certificate received from Link Intime India Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2024.

pdf

Bliss GVS Pharma Ltd.

09 Jul 2024

152.19

-0.84%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

We would like to inform you that, the ESOP Allotment Committee of the Company at its meeting held on July 09, 2024, has approved the allotment of 83,000 equity shares of the face value of Re.1/- each to the eligible employees who have exercised their stock options under Bliss GVS Pharma Limited - Employee Stock Option Plan 2019 ("Bliss GVS ESOP-2019").

pdf

Bliss GVS Pharma Ltd.

05 Jul 2024

152.19

-0.84%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pursuant to Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisements pertaining to the Notice of 39th Annual General Meeting of the Company scheduled to be held on Thursday, July 25, 2024, at 11:00 a.m. (IST) through Video Conferencing/Other Audio-Visual Means, e-Voting, and Book Closure.

pdf

Bliss GVS Pharma Ltd.

03 Jul 2024

152.19

-0.84%

Corp. Note

BLISS GVS PHARMA LTD. - 506197 - Business Responsibility and Sustainability Reporting (BRSR)

BSE India

Please find enclosed the Business Responsibility and Sustainability Report for the financial year 2023-2024, which forms an integral part of the Annual Report for the financial year 2023-2024.

pdf

Bliss GVS Pharma Ltd.

03 Jul 2024

152.19

-0.84%

AGM

BLISS GVS PHARMA LTD. - 506197 - Notice Of The 39Th Annual General Meeting ('AGM') Of …

BSE India

Please find enclosed herewith the Notice of the 39th AGM of Bliss GVS Pharma Limited ("the Company") scheduled to be held on Thursday, July 25, 2024 at 11:00 a.m.(IST) through VC/OAVM. The said Notice forms part of the Annual Reportof the Company for the financial year 2023-2024.

pdf

Bliss GVS Pharma Ltd.

03 Jul 2024

152.19

-0.84%

Corp. Note

BLISS GVS PHARMA LTD. - 506197 - Reg. 34 (1) Annual Report.

BSE India

This is further to our letter dated May 02, 2024, wherein the Company informed that the 39th Annual General Meeting (39th AGM) of the Company is scheduled to be held on Thursday, July 25, 2024, through Video Conference/Other Audio-Visual Means, in accordance, with the relevant circulars issued by Ministry of Corporate Affairs ('MCA') and Securities and Exchange Board of India ('SEBI'). Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), please find enclosed the Notice convening the 39th AGM and the Annual Report of the Company including Business Responsibility and Sustainability Report, for the financial year 2023-2024.

pdf

Bliss GVS Pharma Ltd.

01 Jul 2024

152.19

-0.84%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pursuant to Regulation 30 and Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the copies of the newspaper notice in the interest of the shareholders regarding the intimation of 39th Annual General Meeting of the Company scheduled to be held on Thursday, July 25, 2024, at 11:00 a.m. (IST) through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM"), published in the "The Economics Times, Free Press Journal, Maharshtra Times and Navshakti" newspaper on June 29, 2024.

pdf

Bliss GVS Pharma Ltd.

28 Jun 2024

152.19

-0.84%

SAST

BLISS GVS PHARMA LTD. - 506197 - Closure of Trading Window

BSE India

This is to inform you that pursuant to the Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory modification(s) or re-enanctment(s) thereof, for the time being in force) and in accordance with the Code of Internal Procedures and Conduct for Regulating, Monitoring, and Reporting of Trading by Designated Persons, the Trading window for dealing in securities/shares of Bliss GVS Pharma Limited ("the Company") will remain closed for Insiders, Designated Persons and their immediate relatives of the Company with effect from Monday, July 01, 2024 till completion of 48 hours after the announcement of the Unaudited Financial Results of the Company for the quarter ended on June 30, 2024 generally made availabe to the public.

pdf

Bliss GVS Pharma Ltd.

22 Jun 2024

152.19

-0.84%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Intimation Regarding The Appointment Of Additional Non-Executive Independent Director

BSE India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that, subject to approval of shareholders in ensuing 39th Annual General Meeting and based on recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company through circular resolution approved on June 22, 2024 have appointed Dr. Nandkumar Kashinath Chodankar (DIN:02736718) as a Additional Director in the category of Non-Executive Independent Director of the Company for a period of 5 yrs w.e.f. June 22, 2024. Please find enclosed the intimation is this regard.

pdf

Bliss GVS Pharma Ltd.

21 Jun 2024

152.19

-0.84%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations …

BSE India

Disclosure pursuant to Regulation 30 of the SEBI LODR Regulations 2015 is enclosed.

pdf

Is Bliss GVS Pharma Ltd. worth buying?

169 Votes:

Buy 81.07%

Sell 8.88%

Hold 10.06%